Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Common Equity (2022 - 2025)

Ascentage Pharma Group International posted quarterly Common Equity of $188.1 million for Q4 2025, up 411.46% year-on-year from $36.8 million in Q4 2024, and up 411.46% on a QoQ basis from $36.8 million in Q4 2024.

Ascentage Pharma Group International (AAPG) has 4 years of Common Equity data on file, last reported at $188.1 million in Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 411.46% year-over-year to $188.1 million; the trailing twelve-month figure through Dec 2025 stood at $188.1 million (up 411.46% YoY), and the FY2025 full-year result was $190.8 million, up 657796.55% from the prior year.
  • Common Equity for Q4 2025 stood at $188.1 million, up from $36.8 million in the prior quarter.
  • Across five years, Common Equity topped out at $188.1 million in Q4 2025 and bottomed at $9.8 million in Q4 2023.
  • The 4-year median for Common Equity is $47.1 million (2022), against an average of $73.0 million.
  • The widest annual swing landed in 2023, when Common Equity tumbled 82.93%; it then soared 411.46% in 2025.
  • A 4-year view of Common Equity shows it stood at $57.5 million in 2022, then sank by 82.93% to $9.8 million in 2023, then soared by 274.93% to $36.8 million in 2024, then jumped by 411.46% to $188.1 million in 2025.
  • The last three Common Equity figures came in at $188.1 million (Q4 2025), $36.8 million (Q4 2024), and $9.8 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -1.42 Mn
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - 35.63 Mn
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn 1.00 Bn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - 14.38 Mn
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 19.36 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 31.42 Bn
8 Evaxion A 65.44 Bn 65.42 Bn - 13.21 Mn
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 1.08 Bn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn - 188.11 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 188.11 Mn
Dec 31, 2024 36.78 Mn
Dec 31, 2023 9.81 Mn
Dec 31, 2022 57.46 Mn